Takeda Pharmaceutical (TAK) stock

Medicines , market cap $68B

Medicines for oncology and rare diseases

Worth $68B

$20.93

-0.76%

As of Tuesday's close · Live for Pro members at the open

Quality Score

Excellent

In its industry

#22of 281

Biotech

Checks firing

6of 14

Trending up

From 52-week high

-3.7%

under its best in a year

TAK's Quality Score fell 2 points on Tue, Nov 10, to 15. Trading picked back up (2 chart checks stopped).

Follow TAK's trial news. Pro members can get an alert when Takeda Pharmaceutical files news, and see its trials, share raises, and its CEO's filings.

Get an alert when TAK files news on its trialsSee it live, free until Thursday morning. No account. No card. Then keep going with a free account.

We do the work for you. Every stock is scored and ranked, every 15 seconds while the market is open. Here it's 15 minutes behind. Pro members see it live.

NextQ1 2027“The FDA has set a Prescription Drug User Fee Act (PDUFA) goal date in the first quarter of calendar year 2027.”FDA decision date · SEC filing · Oct 29

Why TAK ranks #199 of 3,146

Up 56% over the past year while the S&P 500 rose 12%.

“The increase in revenue mainly reflects foreign exchange benefits.”

Takeda Pharmaceutical's Oct 29 release said

Sources: Price history, Nov 9, 2026; Company release, Oct 29, 2026

1 more reason, free with an account →3 more reasons behind TAK's #151, from its filings, with the company's words and the timeline, for Pro members.

Key facts on TAK

Key facts on TAK
The chart	5 weeks above its 50-day
Latest filing	20-F, Jun 25 Filed its annual report (20-F) for the year to Mar 31, 2025

1 more reason behind TAK's 15, free with an account →4 more reasons behind TAK's 15, for Pro members.

What's next

Tue Nov 10: Financial Times Global Pharma and…Industry event · date confirmed.

TAK catalysts

Coming up

After its last 4 reports it closed +0.2% on average, higher 2 of 4 times.

30 past catalysts since 2019, with sizes and sources, for Pro members.

What's next for TAK

Next step the company has named

Q1 2027“The FDA has set a Prescription Drug User Fee Act (PDUFA) goal date in the first quarter of calendar year 2027.”FDA decision date · SEC filing · Oct 29

What it means: the date by which the FDA has said it aims to decide on the company’s application. The FDA can decide earlier, or extend the date.

A trial underway: TAK-861 for the Treatment of Narcolepsy With CataplexyPhase 3 · Active · 98 people · main data estimated Dec 17, 2026 · NCT07363720

75 more trials, 2 with data due this year, 26 drugs past Phase 1, 1 drug news item, and 118 filings, for Pro members.

Dilution on the horizon

Shelf registration (F-3ASR, filed Jun 26, 2024)

For Pro members: the amounts, and the share count against a year ago.

Insiders

President, IBU Richard Platford Giles sold 55,617 shares on Nov 4. 20 more insider trades this year.

From Form 4: open-market buys and sales only.

Get an alert when Julie Kim buys or sells

For Pro members: every trade, and Julie Kim’s 7 filings and quotes.

Get an alert when TAK files news on its trialsA free account. No card.

See every upcoming FDA date →

FDA dates in the next 60 days

Decision dates and advisory committee meetings the companies have announced in their filings, soonest first and small companies first.

DateStockDrug

In 12 daysFDA decisionIn 12 days · FDA decisionCAPRCapricor TherapeuticsDeramiocelCAPRCapricor Therapeutics · $500MDeramiocelFDA decision due (PDUFA)
In 12 daysFDA decisionIn 12 days · FDA decisionSVRASavaraMolgramostimSVRASavara · $900MMolgramostimFDA decision due (PDUFA)
In 42 daysFDA decisionIn 42 days · FDA decisionMLYSMineralys TherapeuticsLorundrostatMLYSMineralys Therapeutics · $1.3BLorundrostatFDA decision due (PDUFA)

14 more FDA dates and 103 trial data dates in the next 60 days, each on the FDA calendar. Pro members see whether each company's cash lasts past its date, with an optional alert before it. See all 151 dates, ranked →

Why TAK scores 15

Excellentfor quality, not price, 6 of 14 chart checks firingWhat the Quality Score means

+6Chart checks 6 of 14 firing right now, one point each
+4Long-term trend above a rising 200-⁠day average, near its 52-⁠week high, at a multi-⁠year high

Size adds
Profit addsRead on the last four quarters against the four before, or the last full year where no quarters are filed.
Persistence adds
News adds
Insider trades subtracts

No effect today: Run-up, Growth, Dilution, Volatility, and Cash flow.

What every line is worth, and the reason behind it, on TAK and every other stock.Get in free →

Price, score, chart checks, and the industry rank are from a snapshot taken at 11:29 PM ET, at least 15 minutes behind. How we rank stocks.

Tested. Our top-scored stocks returned 2.2x the average stock over the next month. Reconstructed after the fact; recorded live since Sep 9, 2026. How we tested it

Alert me when TAK's Quality Score turns up

A free account. No card.

How TAK ranks in Biotech

TAK is #22 of 281 by Quality Score.

How TAK ranks in Biotech
Rank	Stock	Checks	Quality Score
1	ONCBeOne Medicines	8/14	24
2	VCELVericel	8/14	22
3	ETONEton Pharmaceutcials	9/14	20
	STROSutro Biopharma		Open for its score
	SYRESpyre Therapeutics		Open for its score
	TARAProtara Therapeutics		Open for its score
	TARSTarsus Pharmaceuticals		Open for its score
22	TAKTakeda Pharmaceutical	6/14	15

When does TAK report earnings, and what happens after?

Reports Thu Jan 28, before the open (in 79 days). Confirmed.

What an earnings report is: every 3 months, a company tells everyone how much it sold and earned. We read the figures, the outlook, and how the stock moved after.

Close after the report, last 3

+1.3%-2.8%-0.7%

May 13Jul 30Oct 29

Reported	When	Gap	Reaction	5 days
Oct 29, 2026Before open	Before open	-0.7%	-0.7%	+4.5%
Jul 30, 2026Before open	Before open	-4.0%	-2.8%	-5.8%
May 13, 2026Before open	Before open	-2.0%	+1.3%	+1.0%

TAK closed higher after 2 of its last 4 reports.

All 4 reports, and TAK's Quality Score going into each

TAK has 6 of 14 chart checks firing

Trend1 of 5 shown

MA FAN 21 EMA W.EMA HH/HL 52W HI

Volume1 of 3 shown

VOL VDU U/D VOL

Tight range1 of 3 shown

ATR SQZ SQUEEZE NR7

Buying1 of 3 shown

OBV+CLOSE HI SPRING

The other 10 checks on TAK, and all 14 on every stock.Get in free →

TAK RSI today: 65.6, above its 50-day and 200-day averages

Not scored

RSI 65.6, MACD above signal, above both averages. Not scored.13 readings

The deep dive on TAK

What it does and how it makes money3 findings"Furthermore, our current top selling product, ENTYVIO, will face loss of regulatory exclusivity in the latter half of this decade and certain patents covering various aspects of this product are expected to expire in 2032." (20-F for fiscal 2025)SEC filing · Jun 25, 2025
Where it stands1 findingPaid $0.31 a share in dividends over the last year, in 1 payment.Ex-dividend dates and amounts, from the market data vendor
What changed in its filings4 findings"In March 2025, four individual retail pharmacies filed a civil action in the U.S. District Court for the Northern District of California against Takeda and Twi Pharmaceuticals, Inc. ('Twi'), a generic pharmaceutical manufacturer …" (20-F for fiscal 2025)SEC filing · Jun 25, 2025A new heading in its "Risk Factors" this year: "Restructuring initiatives to improve efficiency in our business may not provide the expected benefits on the expected timeline." (20-F for fiscal 2025; not in fiscal 2024's)SEC filing · Jun 25, 2025, against the one of Jun 26, 2024
Who holds and trades it4 findingsFor Pro members4 findings on who holds and trades TAK, for Pro members
Against its closest peers4 peersFor Pro membersTAK against 4 peers, fact by fact, for Pro members

8 more findings on TAK, each with its source, for Pro members.

TAK share count over time

Offerings, shelves, and splits of TAK, from its filings
From its filings	Filed
Registered shares for a later sale (F-3ASR)	Jun 25, 2025
Registered shares for a later sale (F-3ASR)	Jun 26, 2024

TAK insider trades

13 insiders sold $12.7M across 20 filings in the last 6 months. No open-⁠market buys on record. The newest:

SellRichard Platford Giles$1.2MPresident, IBUat $20.90 on Nov 4, filed Nov 5

SellRichard Platford GilesPresident, IBU$1.2Mat $20.90 on Nov 4, filed Nov 5

All 20 insider filings on TAK from the last six months, for Pro members.

All TAK insider trades

TAK trades by Congress and the executive branch

One trade disclosed in the last six months. The newest:

BuyRo Khanna$1K to $15KHousetraded Oct 9, disclosed Nov 5(27 days later)

BuyRo KhannaHouse$1K to $15Ktraded Oct 9, disclosed Nov 5(27 days later)

See what Congress is buying across the market

TAK's officers and directors

Officers and directors with a Form 4 in the last 12 months.

Julie So-Young KimPresident and CEO · 1 trade
Christophe Pierre WeberPresident and CEO · no trades on file
Milano FurutaChief Financial Officer · no trades on file
Nicola Deidre Petal GreenwayChief Human Resources Officer · 4 trades
Andrew Stewart PlumpPresident, R&D · 3 trades
Elaine Mary ShannonPres., Global Supply & Quality · 2 trades
Lauren Rusckowski DupreyChief Transformation Officer · 2 trades
Richard Platford GilesPresident, IBU · 2 trades

17 more officers and directors file at TAK.

See insider trades by person

About Takeda Pharmaceutical

Takeda Pharmaceutical is Japan's largest pharmaceutical company, with revenue of JPY 4.5 trillion in fiscal 2025. The company's five core therapeutic areas are oncology, gastroenterology, neuroscience, rare diseases, and plasma-derived therapies, which account for more than 80% of revenue. Its geographic footprint is well diversified, with about 50% from the US, 10% from Japan, 25% from Europe, and 15% from Canada.

47,029 employeestakeda.com

What Takeda Pharmaceutical says it competes with

“Competition in each market where we conduct business is based on, among other things, product safety, efficacy, convenience of dosing, reliability, availability and pricing.”

From its annual report, SEC filing · Jun 25, 2025

Here is what Pro members see.

The same page for Pro members, on Microsoft
Its Quality Score and rank, the line that drives it, and the live price.
The full chart
A year of candles to start, out to the whole history, with insider trades marked and the Quality Score under the price.
Every line of the score
Price action, the company, and signals, each with its points, on TAK and every other stock.
FDA dates, counted down
Each date in the company's words, its cash against the date, and an optional alert before it.
CEOs buying their own stock
Every CEO buy, biggest names first. Sort, filter, save the list, and set optional alerts.
Congress trades
A member's trades, newest first, each with its amount. Sort and filter the whole list.
14 chart checks, read for you
The ones firing on the stock, each in plain words, its rule a tap away.
Earnings, week by week
Who reports each day, and how each stock took its last four reports.
The market map
Every stock a box, colored by its Quality Score.
Themes, ranked live
Each theme's stocks ranked by Quality Score, live. Here, AI chips.
The top 10, every day
The ten highest Quality Scores at each close, kept day by day, week by week.
Optional alerts, your way
Pick a stock, a score, a price, a filing, or a whole scan. It tells you by push or email.
Your watchlist, scored
Your stocks by Quality Score, today's move, or name.
On your phone and your laptop
The same account and watchlist on both, each laid out for its screen.

Prices refresh every 2.5 seconds during market hours.
Optional alerts by push, email, or the bell.
Add it to your Home Screen and it opens like an app.

Pro members see every line of every stock's score.

What would move TAK's score: 3 things
4 more filings explained, a plain line each
Real-⁠time prices, no delay

BreakawayNov 5Ro Khanna bought TAK$1K to $15K, disclosed Nov 5

Alerts are optional.

See TAK's 14 chart checks

See it live, free until Thursday morning. No account. No card. Then keep going with a free account.

Straight AnswersStraight Answers

As of Nov 10, 2026: TAK's Quality Score is 15 (Excellent), #22 of 281 in Biotech. Insiders sold $12.7M in the last 6 months (Form 4).

What does TAK's Quality Score say?

TAK scores 15 today, which Breakaway calls Excellent. It is #22 of 281 in Biotech by Quality Score, with 6 of 14 chart checks firing. Up 56% over the past year while the S&P 500 rose 12%. Breakaway does not say whether to buy any stock: the score does not know your situation, and it is not a recommendation to buy or sell anything. Please do your own research.

What is TAK's Quality Score?

TAK scores 15 today, which Breakaway calls Excellent (15 to 19). That is #22 of 281 in Biotech by Quality Score. The score adds up the chart checks, the trend, the company's filed sales, its profits, the news, insider trades, and Congress trades. The section above lists the lines behind TAK's 15.

Are insiders buying TAK?

13 insiders sold $12.7M across 20 filings in the last 6 months. No open-⁠market buys on record. The newest is Richard Platford Giles, President, IBU, who sold $1.2M on Nov 4. Every filing, with the scored weight, for Pro members.

Are the prices delayed?

Only on the public pages, which run at least 15 minutes behind. Pro members, and anyone on a guest pass, see real-time prices: the scanner refreshes every 15 seconds, and your watchlist every few seconds, pre-market and after hours included.